Kazia Therapeutics Limited
Kazia Therapeutics Limited is an Australian oncology-focused drug development company headquartered in Sydney and listed on Nasdaq under KZIA. Its portfolio centers on paxalisib, an investigational brain-penetrant PI3K/Akt/mTOR inhibitor, alongside discovery programs targeting mechanisms of tumor immune evasion and treatment resistance.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage development of a brain-penetrant PI3K/Akt/mTOR pathway inhibitor for cancer indications.
Preclinical platform designed to address tumor immune evasion and resistance to immunotherapy.
Discovery platform targeting SETDB1 biology in aggressive, metastatic, and immunotherapy-resistant solid tumors.
Customers
Kazia is a development-stage biotechnology company and has not disclosed commercial product revenue or an established customer base. Its primary external stakeholders are oncology patients, clinical investigators, hospitals, research institutions, regulators, and potential pharmaceutical partners evaluating its investigational programs. Future commercial customers would likely include healthcare providers and oncology treatment networks purchasing approved therapies, while strategic partners could license or co-develop Kazia assets.
Hospitals, academic centers, and investigators conduct trials of paxalisib and other candidates.
Patients with cancers such as glioblastoma and triple-negative breast cancer are the intended beneficiaries of development programs.
Potential licensees or co-development partners provide development, commercialization, or financing capabilities.
Regulators and research organizations evaluate clinical evidence, safety, and translational data.
Strategy
Kazia’s strategy is centered on advancing paxalisib across selected oncology indications while building a broader pipeline around treatment resistance and tumor immune evasion. The company is also developing earlier-stage PD-L1 degrader and SETDB1 inhibitor programs to reduce reliance on a single clinical asset and create additional partnering opportunities. Progress depends on generating clinical evidence, securing funding, and converting scientific findings into regulatory and commercial value.
Clinical validation is the main route to regulatory approval and future commercial value.
Additional mechanisms can diversify the portfolio beyond the lead asset.
Partnerships and capital are needed to fund trials and support eventual commercialization.
Geography
Kazia is headquartered in Sydney, Australia, and reports to U.S. investors as a foreign private issuer through Form 20-F and Form 6-K filings. Its clinical and research activities are internationally oriented, with paxalisib development addressing oncology indications relevant to global pharmaceutical markets. No country-level revenue or authoritative geographic revenue split was disclosed in the available reports.
Risks
Kazia’s value is concentrated in investigational oncology programs, particularly paxalisib, so unfavorable clinical results, safety findings, or regulatory decisions could materially impair the business. The company also faces biotechnology funding and dilution risk because clinical development requires substantial capital before product revenue. Competitive drug discovery, intellectual-property limitations, licensing obligations, manufacturing requirements, and difficulty translating preclinical findings into patient benefit add further uncertainty.
The lead asset remains investigational and requires convincing efficacy and safety data across cancer indications.
Exposure: Paxalisib clinical programs
Clinical evidence may not satisfy regulators or may lead to additional trials and delays.
Exposure: All drug candidates
Long oncology development timelines require external financing before meaningful commercial revenue.
Exposure: Clinical and platform development
Dependence on paxalisib increases sensitivity to setbacks in its clinical or partnering trajectory.
Exposure: Lead program
Paxalisib was licensed from Genentech, making rights, royalties, obligations, and patent duration relevant to value capture.
Exposure: Licensed paxalisib asset
Accounting
Judgemental itemsClinical trials and discovery programs are generally expensed as incurred, creating substantial losses before commercialization.
Impact: Reported earnings and operating cash flow
Licensed or acquired drug rights may lose value if clinical, regulatory, or commercial prospects deteriorate.
Impact: Non-cash impairment expense and asset carrying values
Paxalisib licensing arrangements may include milestone payments, royalties, or other obligations dependent on development outcomes.
Impact: Future expenses, liabilities, and economics of commercialization
Pre-funded and other warrants can require fair-value assessment and may produce non-cash volatility or dilution.
Impact: Net income, liabilities, and diluted share count
A development-stage company without established product revenue must continually assess whether available funding supports planned operations.
Impact: Financial statement disclosures and financing interpretation
Similar listed companies
Publicly listed companies with a comparable business focus.
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Pacira BioSciences, Inc.
PCRX · Pharmaceutical Preparations
Pacira BioSciences is a U.S.-based biopharmaceutical company focused on non-opioid pain management products.
Jazz Pharmaceuticals plc
JAZZ · Pharmaceutical Preparations
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on medicines for serious diseases, with a portfolio centered on neuroscience and oncology.
Radiopharm Theranostics Ltd
RADX · Pharmaceutical Preparations
Radiopharm Theranostics Ltd is an Australia-based clinical-stage radiopharmaceutical company developing diagnostic and therapeutic products for cancer.
Last updated: 08/09/2026